A5027874476- Lymphoma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- RNA Research and Splicing
- Chronic Lymphocytic Leukemia Research
- Genetic factors in colorectal cancer
- RNA modifications and cancer
- CAR-T cell therapy research
- Viral-associated cancers and disorders
- Lung Cancer Treatments and Mutations
- Genomics and Phylogenetic Studies
- Cancer-related molecular mechanisms research
- Molecular Biology Techniques and Applications
- Pancreatic and Hepatic Oncology Research
- Gene expression and cancer classification
- Single-cell and spatial transcriptomics
Simon Fraser University
2016-2023
Abstract Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer originating from mature B-cells. Prognosis strongly associated with molecular subgroup, although the driver mutations that distinguish two main subgroups remain poorly defined. Through integrative analysis of whole genomes, exomes, and transcriptomes, we have uncovered genes non-coding loci are commonly mutated in DLBCL. Our has identified novel cis -regulatory sites, implicates recurrent 3′ UTR NFKBIZ as a mechanism...
Follicular lymphoma (FL) accounts for ∼20% of all new cases. Increases in cytological grade are a feature the clinical progression this malignancy, and eventual histologic transformation (HT) to aggressive diffuse large B-cell (DLBCL) occurs up 15% patients. Clinical or genetic features predict risk timing HT have not been described comprehensively. In study, we analyzed whole-genome sequencing data from 423 patients compare protein coding noncoding mutation landscapes untransformed FL,...
Abstract The field of cancer genomics has demonstrated the power massively parallel sequencing techniques to inform on genes and specific alterations that drive tumor onset progression. Although large comprehensive sequence data sets continue be made increasingly available, analysis remains an ongoing challenge, particularly for laboratories lacking dedicated resources bioinformatics expertise. To address this, we have produced a collection Galaxy tools represent many popular algorithms...
Abstract Mantle cell lymphoma (MCL) is an uncommon B-cell non-Hodgkin (NHL) that incurable with standard therapies. The genetic drivers of this cancer have not been firmly established and the features known to contribute differences in clinical course remain limited. To extend our understanding biological pathways involved malignancy, we performed a large-scale genomic analysis MCL using data from 51 exomes alongside previously published exome cohorts. confirm findings, re-sequenced genes...
Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer originating from mature B-cells. Many known driver mutations are over-represented in one of its two molecular subgroups, knowledge which has aided the development therapeutics that target these features. The heterogeneity DLBCL determined through prior genomic analysis suggests incomplete understanding aetiology, with a limited diversity genetic events having thus far been attributed to activated (ABC) subgroup. Through...
Abstract Non-Hodgkin lymphomas (NHL) are a collection of cancers with each malignancy having distinct clinical management and prognosis. Mantle cell lymphoma (MCL) is particularly genetically heterogeneous considered incurable. Through combination exome, genome, targeted sequencing MCL tumors, we identified recurrent mutations in HNRNPH1 (heterogeneous nuclear ribonucleoprotein H1). These largely intronic or silent associated putative cis regulatory region involving single exon. In RNA-seq...